Background β blockers reduce mortality in patients who have chronic heart failure, systolic
dysfunction, and are on background treatment with diuretics and angiotensin-converting …

BACKGROUND: β-Blockers with different receptor bindings reduce mortality in patients with
chronic heart failure. We compared the effects of the β1-blocker metoprolol tartrate and the …

In large clinical trials both carvedilol and metoprolol have been shown to reduce mortality
and morbidity in patients with chronic heart failure. Carvedilol is an adrenoceptor antagonist …

Background Beta-blocking agents reduce the risk of hospitalization and death in patients
with mild-to-moderate heart failure, but little is known about their effects in severe heart …

Background: Many patients remain markedly symptomatic despite optimal current therapy
for heart failure. Beta-blockers have often been viewed as contraindicated in this group …

Background Controlled clinical trials have shown that beta-blockers can produce
hemodynamic and symptomatic improvement in chronic heart failure, but the effect of these …

Background Carvedilol has improved the symptomatic status of patients with moderate to
severe heart failure in single-center studies, but its clinical effects have not been evaluated …

Background—β-Blocking agents improve functional status and reduce morbidity in mild-to-
moderate heart failure, but it is not known whether they produce such benefits in severe …

The impact of carvedilol on the survival of patients with severe heart failure was examined in
the Carvedi-lol Prospective Randomized Cumulative Survival (COPERNICUS) trial. The trial …

Context β-Blockers remain underused despite their established utility for improving outcome
in heart failure. Concerns that initiation of treatment produces few immediate benefits and …